FDA discusses establishment of international consortium of CV registries

Dellapena, Deb
May 2013
Cardiology Today;May2013, Vol. 16 Issue 5, p1
The article reports that the U.S. Food and Drug Administration (FDA) is holding discussions on the establishment of the International Consortium of Cardiovascular (CV) Registries, initially focusing on transcatheter aortic valve replacement data collection, to be later expanded to additional CV devices.


Related Articles

  • TAVR superior to surgery for 1-year survival in high-risk patients. Ellis, Brian; Kalvaitis, Katie; Swain, Erik; Taliercio, Adam // Cardiology Today;Apr2014, Vol. 17 Issue 4, p15 

    The article highlights the conclusion of the U.S. Food and Drug Administration (FDA) that transcatheter aortic valve replacement with a self-expanding transcatheter valve was associated with a higher rate of survival, which they declared after comparing it to surgical aortic valve replacement (AVR).

  • Terumo Heart wins 'conditional' approval for its DuraHeart trial.  // Medical Device Daily;3/5/2008, Vol. 12 Issue 44, p10 

    The article reports on the conditional U.S. Food and Drug Administration (FDA) approval received by Terumo Heart to begin enrollment in the U.S. trial of the DuraHeart LVAS for bridge-to-transplant device. The approval was granted pending answers to some additional questions. The device is a...

  • CryoLife reports implantations of pulmonary cardiac patch.  // Medical Device Daily;8/19/2009, Vol. 13 Issue 159, p10 

    The article reports that three patients have been implanted with the CryoPatch SG pulmonary human cardiac patch from CryoLife. The said patch is part of the SynerGraft technology platform of the company and has been given clearance by the Food and Drug Administration (FDA) in the U.S. There are...

  • Artificial Aortic Heart Without Open-Heart Surgery.  // Biotech Business;Dec2011, Vol. 24 Issue 12, p1 

    The article reports on the approval of the first catheter-based aortic heart valve replacement without the need for open-heart surgery by the U.S. Food and Drug Administration (FDA). The transcatheter aortic valve replacement (TAVR) allows multi-disciplinary heart teams to substitute the...

  • HEALING BROKEN HEARTS. Wessel, Harry // Orlando Life;Jun2013, Vol. 14 Issue 6, p30 

    The article presents a discussion on a new medical procedure called transcatheter aortic valve replacement (TAVR). The said procedure was approved by the U.S. Food and Drug Administration (FDA) in November 2011 and was first performed in February 2012 with patient Duyane Hoffman. It is said to...

  • Claret Montage Dual Filter gains support from study. FORD, OMAR // Medical Device Daily;5/21/2013, Vol. 17 Issue 98, p1 

    The article reports on a study by cardiologist Nicolas Van Mieghem which can provide credence to a device for cleaning up embolic debris after Transcatheter Aortic Valve Replacement (TAVR) developed by Santa Rosa, California-based medical device company Claret Medical. Van Mieghem's study...

  • Medtronic gets FDA nod for CoreValve IDE clinical study. Ford, Omar // Medical Device Daily;10/18/2010, Vol. 14 Issue 202, p1 

    The article reports that the U.S. Food and Drug Administration has given conditional approval to Medtronic for its investigational device exemption (IDE) application and pivotal clinical trial protocol to assess its CoreValve system for transcatheter aortic valve implantation (TAVI). The device...

  • Transcatheter Aortic Valve Replacement. Feldman, Arthur M.; DiSesa, Verdi J. // JAMA: Journal of the American Medical Association;7/2/2014, Vol. 312 Issue 1, p25 

    The authors comment on the approval by the U.S. Food and Drug Administration (FDA) of transcatheter aortic valve replacement (TAVR) for the treatment of patients considered inoperable and the expansion of the indication to include patients at high risk of surgical aortic valve replacement...

  • Proposed Rules: DEPARTMENT OF HEALTH AND HUMAN SERVICES.  // Federal Register (National Archives & Records Service, Office of;1/7/2014, Vol. 79 Issue 4, p765 

    The article presents notice from the Department of Health and Human Services and Food and Drug Administration regarding its proposed order in the U.S. It provides summary and supplementary information of the proposed ruling that focused on cardiovascular devices such as cardiopulmonary bypass...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics